Evidence map›Paper›PMID 39123156›Full record

ArticleBMC endocrine disorders2024

Incomplete ablation of thyroid cancer: Achilles' Heel?

Ze Yang, Xue-Hua Pan, Heng-Tong Han, Yong-Xun Zhao, Li-Bin Ma

Abstract readCase Reports
In one paragraph

Article in BMC endocrine disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ze YangThe Seventh Department of General Sur gery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, 730000, China.
Xue-Hua PanThe Third People's Hospital of Gansu Province, Lanzhou, Gansu Province, 730000, China.
Heng-Tong HanThe Seventh Department of General Sur gery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, 730000, China.
Yong-Xun ZhaoThe Seventh Department of General Sur gery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, 730000, China.
Li-Bin MaThe Seventh Department of General Sur gery, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, 730000, China. malb2012@126.com.

Funding

Gansu Provincial Education Science and Technology Innovation Project No2022B-017Natural Science Foundation of Gansu Province, China No. 17JR5RA272Research Fund project of The First Hospital of Lanzhou University No. ldyyyn2020-98Research Fund project of The First Hospital of Lanzhou University No. ldyyyn2021-120Research Fund project of The First Hospital of Lanzhou University No. ldyyyn2021-30
6 · The paper itself

Abstract

backgroundIn recent years, the incidence of thyroid nodules has increased significantly. There are various ways to treat thyroid nodules, and ablation therapy is one of the important ways to treat thyroid nodules. However, there are many complications and deficiencies in the current ablation treatment of thyroid nodules, especially the incomplete ablation of thyroid cancer nodules, which limits the further application of ablation technology. In this paper, we report two cases of incomplete ablation of thyroid nodules, one of which underwent surgical treatment due to anxiety after ablation, and the postoperative pathology confirmed that there was still residual papillary thyroid carcinoma, and the other patient underwent an operation after ablation, but visited our medical institution again due to cervical lymph node metastasis in a short period of time, and after radical cervical lymph node dissection, pathology confirmed multiple cervical lymph node metastasis. Radionuclide therapy was performed after surgery, and two patients are currently receiving endocrine suppression therapy, and their condition is stable with no signs of recurrence.

conclusionThe incomplete ablation of thyroid cancer nodules limits the development of ablation therapy, making ablation treatment a double-edged sword. Guidelines and expert consensus can guide their development, but they need to evolve with the times, and a multidisciplinary diagnostic team can help screen the most suitable patients. Only by using this technology more standardly, using the most appropriate technology, and treating the most suitable patients, can benefit more and more patients.

Indexed as

Thyroid NeoplasmsAblation TechniquesAdultFemaleHumansIodine RadioisotopesLymphatic MetastasisMaleMiddle AgedThyroid Cancer, PapillaryThyroid NoduleIodine RadioisotopesAblationCase reportMDTPTMCThyroid nodules

Identifiers

PMID39123156
PMCPMC11313020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.